Atara Biotherapeutics Inc Forecast, price target & analysts
Atara Biotherapeutics Inc Target price 2025 - Analyst rating & recommendation
Atara Biotherapeutics Inc Classifications & Recommendation:
Atara Biotherapeutics Inc Price Target
| Target Price | $16.00 |
| Price | $8.82 |
| Potential |
81.41%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Atara Biotherapeutics Inc 2026 .
The average Atara Biotherapeutics Inc target price is $16.00.
This is
81.41%
register free of charge
$18.00
104.08%
register free of charge
$13.00
47.39%
register free of charge
|
|
| A rating was issued by 4 analysts: 4 Analysts recommend Atara Biotherapeutics Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Atara Biotherapeutics Inc stock has an average upside potential 2026 of
81.41%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 128.94 | 86.63 |
| 1,404.55% | 32.81% | |
| EBITDA Margin | -56.83% | 66.95% |
| 98.16% | 217.80% | |
| Net Margin | -66.23% | 22.82% |
| 97.94% | 134.45% |
3 Analysts have issued a sales forecast Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Atara Biotherapeutics Inc Analysts have issued a net profit forecast 2025. The average Atara Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -11.41 | 3.34 |
| 82.49% | 129.27% | |
| P/E | 2.64 | |
| EV/Sales | 1.01 |
2 Analysts have issued a Atara Biotherapeutics Inc forecast for earnings per share. The average Atara Biotherapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Atara Biotherapeutics Inc...
Current Atara Biotherapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jan 17 2025 |
| Rodman & Renshaw |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 21 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 22 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jan 17 2025 |
|
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 21 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
